EAGLE PHARMACEUTICALS, INC. Insider Trading for February 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in EAGLE PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in EAGLE PHARMACEUTICALS, INC. for February 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | X | 0.00 | 1,614 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 9,359 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 62,575 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | X | 0.00 | 98,368 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 569,538 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 850,520 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 1,028,613 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 1,927,986 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | X | 0.00 | 357 | 0 | 72,291 | 71.9 K to 72.3 K (+0.50 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 9,359 | 0 | 71,934 | 62.6 K to 71.9 K (+14.96 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 62,575 | 0 | 62,575 | 0 to 62.6 K |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | P | 15.00 | 333,333 | 4,999,995 | 4,770,828 | 4.4 M to 4.8 M (+7.51 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | X | 0.00 | 21,837 | 0 | 4,437,495 | 4.4 M to 4.4 M (+0.49 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 569,538 | 0 | 4,415,658 | 3.8 M to 4.4 M (+14.81 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 850,520 | 0 | 3,846,120 | 3 M to 3.8 M (+28.39 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 1,028,613 | 0 | 2,995,600 | 2 M to 3 M (+52.29 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 1,927,986 | 0 | 1,966,987 | 39 K to 2 M (+4,943.43 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | X | 0.00 | 1,614 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 9,359 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 62,575 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | X | 0.00 | 98,368 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 569,538 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 850,520 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 1,028,613 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 1,927,986 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | X | 0.00 | 357 | 0 | 72,291 | 71.9 K to 72.3 K (+0.50 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 9,359 | 0 | 71,934 | 62.6 K to 71.9 K (+14.96 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 62,575 | 0 | 62,575 | 0 to 62.6 K |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | P | 15.00 | 333,333 | 4,999,995 | 4,770,828 | 4.4 M to 4.8 M (+7.51 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | X | 0.00 | 21,837 | 0 | 4,437,495 | 4.4 M to 4.4 M (+0.49 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 569,538 | 0 | 4,415,658 | 3.8 M to 4.4 M (+14.81 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 850,520 | 0 | 3,846,120 | 3 M to 3.8 M (+28.39 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 1,028,613 | 0 | 2,995,600 | 2 M to 3 M (+52.29 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 1,927,986 | 0 | 1,966,987 | 39 K to 2 M (+4,943.43 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | X | 0.00 | 1,614 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 9,359 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 62,575 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | X | 0.00 | 98,368 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 569,538 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 850,520 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 1,028,613 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 1,927,986 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | X | 0.00 | 357 | 0 | 72,291 | 71.9 K to 72.3 K (+0.50 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 9,359 | 0 | 72,291 | 62.9 K to 72.3 K (+14.87 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 62,575 | 0 | 71,934 | 9.4 K to 71.9 K (+668.61 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | P | 15.00 | 333,333 | 4,999,995 | 4,770,828 | 4.4 M to 4.8 M (+7.51 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | X | 0.00 | 21,837 | 0 | 4,437,495 | 4.4 M to 4.4 M (+0.49 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 569,538 | 0 | 4,415,658 | 3.8 M to 4.4 M (+14.81 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 850,520 | 0 | 3,846,120 | 3 M to 3.8 M (+28.39 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 1,028,616 | 0 | 2,995,600 | 2 M to 3 M (+52.29 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 1,927,986 | 0 | 1,966,987 | 39 K to 2 M (+4,943.43 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | C | 0.00 | 2,887 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | C | 0.00 | 8,572 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | C | 0.00 | 8,580 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Buy | C | 0.00 | 2,887 | 0 | 29,399 | 26.5 K to 29.4 K (+10.89 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Buy | C | 0.00 | 8,572 | 0 | 26,512 | 17.9 K to 26.5 K (+47.78 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Buy | C | 0.00 | 8,580 | 0 | 17,940 | 9.4 K to 17.9 K (+91.67 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | C | 0.00 | 1,443 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | C | 0.00 | 8,571 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Buy | C | 0.00 | 1,443 | 0 | 19,374 | 17.9 K to 19.4 K (+8.05 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Buy | C | 0.00 | 8,571 | 0 | 17,931 | 9.4 K to 17.9 K (+91.57 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | X | 0.00 | 3,438 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | C | 0.00 | 25,376 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | C | 0.00 | 171,109 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Buy | X | 0.00 | 763 | 0 | 1,669,622 | 1.7 M to 1.7 M (+0.05 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Buy | C | 0.00 | 25,376 | 0 | 1,668,859 | 1.6 M to 1.7 M (+1.54 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Buy | C | 0.00 | 171,109 | 0 | 1,643,483 | 1.5 M to 1.6 M (+11.62 %) |